| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 32,721 | -21,589 | -36,541 | -185,962 |
| Depreciation | 184 | 218 | 229 | 448 |
| Share-based compensation | 6,915 | 7,074 | 7,199 | 23,367 |
| Deferred income taxes | 0 | 0 | 0 | 43,239 |
| Reduction in the carrying amount of right-of-use assets | 734 | 724 | 714 | 1,369 |
| Reduction in restructuring liability - non-cash | 5,198 | NaN | NaN | NaN |
| Loss on disposal of fixed assets | 0 | -101 | -1 | -2 |
| Accounts receivable | NaN | 0 | 0 | 0 |
| Prepaid and other assets | 2,984 | -1,450 | -5,295 | -3,883 |
| Accounts payable, accruals and other liabilities | -2,222 | -6,249 | -1,632 | -7,895 |
| Deferred revenue | -1,034 | -21 | -2,415 | -7,198 |
| Restructuring liability | 480 | -4,311 | -12,716 | 30,330 |
| Operating lease liabilities | -719 | -709 | -699 | -1,286 |
| Net cash provided by (used in) operating activities | 28,877 | -23,312 | -40,565 | -99,703 |
| Purchases of property and equipment | 0 | 0 | 10 | 128 |
| Proceeds from disposal of fixed assets | NaN | 0 | NaN | NaN |
| Net cash used in investing activities | 0 | 0 | -10 | -128 |
| Proceeds from issuance of ordinary shares upon exercise of stock options | NaN | 0 | 0 | 0 |
| Proceeds from issuance of ordinary shares in public offering, net-Public Offering | NaN | 0 | NaN | NaN |
| Repurchase of ordinary shares | 6,946 | NaN | NaN | NaN |
| Proceeds from issuance of ordinary shares in at-the-market offering, net | 0 | 0 | -17 | -122 |
| Net cash used in financing activities | -6,946 | 0 | -17 | -122 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 21,931 | -23,312 | -40,592 | -99,953 |
| Cash, cash equivalents and restricted cash, beginning of the year | 308,391 | 331,703 | 472,248 | NaN |
| Cash, cash equivalents and restricted cash, end of the period | 330,322 | 308,391 | 331,703 | NaN |
PROTHENA CORP PUBLIC LTD CO (PRTA)
PROTHENA CORP PUBLIC LTD CO (PRTA)